Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Utilizing Afirma GRID scores to further stratify genomic sequencing classifier-suspicious thyroid nodules.

Created on 14 Nov 2026

Authors

Taryn L Waraksa-Deutsch, Simon Sung, Rajeswari Nagarathinam, Yulan Gong, Juanita R Kcomt, Jobran Mansour, Min Huang, Hormoz Ehya, Shuanzeng Wei

Published in

Cancer cytopathology. Volume 134. Issue 12.

Abstract

The Afirma genomic sequencing classifier (GSC) is used to stratify Bethesda category III/IV thyroid nodules into benign and suspicious groups. However, approximately 50% of GSC-suspicious nodules prove to be benign on final surgical pathology. In this study, the authors investigated whether Afirma GRID (Genomic Resource for Intelligent Discovery) data may provide additional insights into the risk stratification of cytologically indeterminate thyroid nodules.
This retrospective study included thyroid find-needle aspiration samples that had an Afirma test performed. Afirma GRID data, including Molecular Signatures Database-derived scores, were obtained, and nonparametric Mann-Whitney U tests were performed.
In total, 178 Afirma GSC-suspicious cases were identified, of which 77 had surgical follow-up and available GRID scores. Surgical pathology revealed 23 malignancies (17 papillary thyroid carcinomas and six follicular carcinomas), 13 cases of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), and 41 benign cases. The invasion classifiers V1/V2, follicular mesenchymal transition scores, and radiation sensitivity scores indicated statistically significant differences between the benign versus cancer, NIFTP versus cancer, and benign + NIFTP versus cancer groups. Conversely, these four scores showed no statistically significant differences between the benign versus NIFTP and benign versus NIFTP + cancer groups. In addition, the MRPS16::TTC18 fusion was identified in a classic papillary thyroid carcinoma that has not been reported previously.
The findings suggest that NIFTP is molecularly more similar to benign nodules than to carcinoma. The GRID scores demonstrate promising clinical utility for improved risk stratification of Afirma GSC-suspicious thyroid nodules.

PMID:
43031268
Bibliographic data and abstract were imported from PubMed on 14 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 14
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement